Previous studies in other cancers indicated an association between drug-resistance and ALDH+ cells [11], [12], [21], therefore, the effect of DTIC and lexatumumab primarily on the percentage of ALDH+ cells was evaluated as shown in Figure 6 A, B. As can be seen, no changes in the proportion of ALDH+ cells were observed following in vitro treatment with lexatumumab, whereas DTIC reduced the percentage of ALDH+ cells, consequently, increased the percentage of ALDH− cells (Figures 6A and S5A). Here, LDHA is linked to cancer.